Gyre Therapeutics, Inc.

Name: Gyre Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

GYRENasdaqCIK 1124105HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$29.1m, Q2 FY2026

Operating income−$14.4m, Q2 FY2026

Net income−$14.3m, Q2 FY2026

Gyre Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	32.0	27.1	27.2	25.2	25.5	27.9	22.1	29.7	30.6	37.2	22.5	29.1
Cost of revenue	$m	1.2	1.3	1.0	0.8	1.0	1.2	0.9	1.2	1.6	1.7	1.2	2.2
Gross profit	$m	30.9	25.9	26.2	24.5	24.5	26.7	21.2	25.6	28.9	not reported	not reported	not reported
Research and development	$m	3.0	4.6	2.2	3.4	2.8	3.7	3.1	8.4	2.4	4.8	6.7	not reported
Selling, general and administrative	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	7.3	not reported	not reported	not reported	7.9
Operating income	$m	12.8	(91.6)	8.1	3.2	4.2	0.7	2.3	(2.2)	6.9	0.1	(9.4)	(14.4)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	3.7	0.7	2.5	1.5	1.1	0.2	0.9	0.7	1.7	1.3	0.6	(0.2)
Net income	$m	7.5	(81.7)	9.9	4.5	2.9	0.6	4.9	(2.2)	5.9	(1.3)	(18.6)	(14.3)
Diluted EPS	$ per share	0.05	not reported	0.03	0.01	0.01	not reported	0.00	(0.03)	0.03	not reported	(0.10)	(0.12)
Basic EPS	$ per share	0.06	not reported	0.09	0.04	0.01	not reported	0.03	(0.02)	0.04	not reported	(0.10)	(0.12)

Balance sheet

Cash and equivalents$43.3m, Q2 FY2026

Shareholders' equity$107.9m, Q2 FY2026

Gyre Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	2.2	33.5	29.8	16.1	15.9	11.8	15.0	36.5	40.4	49.2	37.5	43.3
Current assets	$m	5.1	57.2	62.7	53.5	54.8	64.8	68.4	91.3	98.6	149	91.7	122
Total assets	$m	10.0	117	122	121	125	125	130	153	159	220	162	199
Current liabilities	$m	1.8	20.0	19.5	15.6	14.7	19.5	19.0	16.9	15.9	23.8	19.8	28.7
Total liabilities	$m	6.4	38.1	33.2	27.6	26.8	27.0	25.5	23.2	22.0	31.4	25.0	34.3
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	3.5	(15.8)	56.6	60.4	63.2	63.3	68.1	92.0	102	62.5	101	108

Cash flow

Operating cash flow−$16.7m, Q2 FY2026

Capital expenditure$262.0k, Q2 FY2026

Gyre Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	7.6	3.4	2.9	(5.5)	1.7	(2.8)	(0.1)	(7.5)	14.2	(5.6)	3.2	(16.7)
Capital expenditure	$m	2.0	2.3	0.2	1.5	0.7	(0.1)	0.1	0.3	0.6	0.1	0.2	0.3
Dividends paid	$m	1.5	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)100.64m, Q2 FY2026

Gyre Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	31.5	78.9	78.9	78.9	103	102	103	102	89.2	104	91.3	101

Shares outstanding: 111.51m at Aug 1, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.